Voluntary Delisting from OTCQB Market

Poolbeg Pharma

26/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240726:nRSZ9154Xa&default-theme=true

RNS Number : 9154X  Poolbeg Pharma PLC  26 July 2024

Poolbeg Pharma plc

 

Voluntary Delisting from OTCQB Market

 

26 July 2024- Poolbeg Pharma (http://www.poolbegpharma.com/)  (AIM: POLB,
OTCQB: POLBF, 'Poolbeg' or the 'Company'), a biopharmaceutical company
focussed on the development and commercialisation of innovative medicines
targeting diseases with a high unmet medical need, announces that it is
voluntarily delisting its ordinary shares ("Ordinary Shares") from trading on
the OTCQB Market due to low trading volume and the associated administrative
requirements. The Company's last day of trading on the OTCQB Market will be
Monday 29 July 2024.

Poolbeg will retain its listing on the London Stock Exchange's AIM Market
under its existing ticker "POLB". The delisting from the OTCQB market will
have no impact on Poolbeg's Ordinary Shares, which will continue to trade on
the AIM Market.

Poolbeg reaffirms its ambitions to be dual listed on a national securities
exchange in the US, such as Nasdaq, subject to meeting their listing
requirements at the appropriate time.

 

Enquiries

 

 Poolbeg Pharma Plc                                                               +44 (0) 207 183 1499

 Jeremy Skillington, CEO

 Ian O'Connell, CFO

  
 Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker)                 +44 (0) 207 220 0500

 Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)

  
 Shore Capital Stockbrokers Ltd (Joint Broker)                                    +44 (0) 207 408 4090

 David Coaten, Harry Davies-Ball (Corporate Advisory), Malachy McEntyre, Isobel
 Jones (Corporate Broking)

 J&E Davy (Joint Broker)                                                          +353 (0) 1 679 6363

 Anthony Farrell, Niall Gilchrist

  
 Optimum Strategic Communications                                                 +44 (0) 208 078 4357

 Nick Bastin, Vici Rabbetts, Elena Bates                                          poolbeg@optimumcomms.com (mailto:poolbeg@optimumcomms.com)

  

 

About Poolbeg Pharma

 

Poolbeg Pharma plc is committed to the development and commercialisation of
innovative medicines targeting diseases with a high unmet medical need, with a
growing emphasis on rare and orphan diseases. Its model focusses upon
developing its exciting clinical assets and commercialising approved and
marketed drugs to support the growth of the Company and the development of its
robust pipeline of innovative products, thereby driving significant value
creation.

 

Poolbeg is led by an experienced leadership team with a history of delivering
significant shareholder value. The team has been strengthened by the
appointment of three former members of the Amryt Pharma plc leadership team,
with the intention of repeating Amryt's success and generating near term
revenues.

 

Poolbeg's clinical programmes target large addressable markets including
cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions
such as obesity with the development of an oral GLP-1R agonist. It uses a
cost-effective development philosophy to generate high quality human data to
support partnering and further development. Its AI-led infectious disease
programmes analyse unique data from human challenge trials to identify
clinically relevant drug targets and treatments, leading to faster development
and greater commercial appeal.

 

For more information, please go to www.poolbegpharma.com
(http://www.poolbegpharma.com/)  or follow us on Twitter
(https://twitter.com/PoolbegPharma)  and LinkedIn
(https://www.linkedin.com/company/poolbeg-pharma/)  @PoolbegPharma.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDQELFLZDLXBBF